^
Association details:
| Biomarker: | HRD + BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/17/2023
Excerpt:
Recommendations...For BRCA1/2-wt/HRD-positive: niraparib for 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or olaparib–bevacizumab for 2 years [ESMO-MCBS v1.1 score: 3; ESCAT score: I-A).
